Veto CAR-T

Veto CAR-T is an allogeneic, donor-derived chimeric antigen receptor (CAR) T-cell therapy being developed by Cell Source for the treatment of blood cancers, specifically B-cell malignancies. Built on the proprietary Veto Cell platform technology licensed from the Weizmann Institute of Science, the therapy utilizes anti-viral CD8 central memory T cells that are genetically modified to express CARs. Unlike conventional allogeneic CAR-T approaches that often require complex gene editing to prevent graft-versus-host disease (GVHD) and host rejection, this platform leverages the natural 'veto' property of the cells. This veto activity allows the donor cells to specifically eliminate host anti-donor T cells that would otherwise reject the graft, while simultaneously avoiding the induction of GVHD. The lead preclinical construct, Veto-CD19CAR, is designed to target CD19-positive malignant cells while maintaining a robust safety profile and persistence in the host immune environment.

Other names

Veto CAR-T cell therapyCell Source Veto CAR-T